Q1 Earnings Forecast for TERN Issued By HC Wainwright

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) – Equities researchers at HC Wainwright issued their Q1 2025 EPS estimates for Terns Pharmaceuticals in a research report issued on Wednesday, November 13th. HC Wainwright analyst E. Arce expects that the company will post earnings of ($0.30) per share for the quarter. HC Wainwright currently has a “Neutral” rating and a $7.50 price target on the stock. The consensus estimate for Terns Pharmaceuticals’ current full-year earnings is ($1.28) per share.

A number of other brokerages also recently weighed in on TERN. Oppenheimer assumed coverage on shares of Terns Pharmaceuticals in a research note on Thursday, October 31st. They set an “outperform” rating and a $82.00 price objective on the stock. BMO Capital Markets reiterated an “outperform” rating and set a $26.00 target price (up from $19.00) on shares of Terns Pharmaceuticals in a report on Monday, September 16th. Finally, JMP Securities increased their price target on Terns Pharmaceuticals from $15.00 to $20.00 and gave the stock a “market outperform” rating in a report on Tuesday, September 10th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Terns Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $27.25.

Terns Pharmaceuticals Stock Down 5.8 %

NASDAQ:TERN opened at $6.17 on Thursday. Terns Pharmaceuticals has a 12-month low of $3.59 and a 12-month high of $11.40. The stock’s fifty day simple moving average is $8.03 and its 200-day simple moving average is $7.46. The firm has a market capitalization of $524.07 million, a P/E ratio of -5.23 and a beta of -0.32.

Institutional Trading of Terns Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Bellevue Group AG bought a new stake in shares of Terns Pharmaceuticals in the 3rd quarter valued at about $8,691,000. Janus Henderson Group PLC boosted its stake in shares of Terns Pharmaceuticals by 40.6% during the 1st quarter. Janus Henderson Group PLC now owns 2,003,263 shares of the company’s stock worth $13,131,000 after acquiring an additional 578,500 shares during the period. Point72 Asset Management L.P. increased its holdings in shares of Terns Pharmaceuticals by 21.1% during the 2nd quarter. Point72 Asset Management L.P. now owns 2,690,376 shares of the company’s stock worth $18,321,000 after acquiring an additional 469,176 shares during the last quarter. Affinity Asset Advisors LLC raised its stake in Terns Pharmaceuticals by 581.8% in the 1st quarter. Affinity Asset Advisors LLC now owns 450,000 shares of the company’s stock valued at $2,952,000 after acquiring an additional 384,000 shares during the period. Finally, Salem Investment Counselors Inc. acquired a new stake in Terns Pharmaceuticals during the 2nd quarter valued at $2,531,000. Institutional investors and hedge funds own 98.26% of the company’s stock.

Insider Buying and Selling at Terns Pharmaceuticals

In other news, Director Jill M. Quigley sold 17,235 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $10.00, for a total value of $172,350.00. Following the completion of the sale, the director now owns 15,000 shares of the company’s stock, valued at approximately $150,000. This represents a 53.47 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Hongbo Lu bought 476,190 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was purchased at an average cost of $10.50 per share, with a total value of $4,999,995.00. Following the completion of the purchase, the director now directly owns 476,190 shares of the company’s stock, valued at $4,999,995. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Company insiders own 15.10% of the company’s stock.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.